| Literature DB >> 24319454 |
Gwendolyn A Thomas1, Marty Alvarez-Reeves, Lingeng Lu, Herbert Yu, Melinda L Irwin.
Abstract
Objective. Breast cancer survivors are highly sedentary, overweight, or obese, which puts them at increased risk for comorbid chronic disease. We examined the prevalence of, and changes in, metabolic syndrome following 6 months of an aerobic exercise versus usual care intervention in a sample of sedentary postmenopausal breast cancer survivors. Design and Methods. 65 participants were randomized to an aerobic exercise intervention (EX) (n = 35) mean BMI 30.8 (±5.9) kg/m(2) or usual care (UC) (n = 30) mean BMI 29.4 (±7.4) kg/m(2). Metabolic syndrome prevalence was determined, as well as change in criteria and overall metabolic syndrome. Results. At baseline, 55.4% of total women met the criteria for metabolic syndrome. There was no statistically significant change in metabolic syndrome when comparing EX and UC. However, adhering to the exercise intervention (at least 120 mins/week of exercise) resulted in a significant (P = .009) decrease in metabolic syndrome z-score from baseline to 6 months (-0.76 ± 0.36) when compared to those who did not adhere (0.80 ± 0.42). Conclusions. Due to a higher prevalence of metabolic syndrome in breast cancer survivors, lifestyle interventions are needed to prevent chronic diseases associated with obesity. Increasing exercise adherence is a necessary target for further research in obese breast cancer survivors.Entities:
Year: 2013 PMID: 24319454 PMCID: PMC3844242 DOI: 10.1155/2013/168797
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Baseline characteristics of participants.
| Characteristic | Exercise | Usual care | Nonadherers | Adherers |
|---|---|---|---|---|
| Age (yr) | 56.5 (9.8) | 55.1 (7.6) | 57.5 (12.8) | 55.7 (6.9) |
| Weight (kg) | 82.1 (16.5) | 77.2 (20.4) | 86.6 (17.0) | 78.7 (15.6) |
| Height (cm) | 161.8 (6.2) | 163.2 (6.5) | 161.3 (5.6) | 164.6 (6.7) |
| BMI (kg/m2) | 30.8 (5.9) | 29.4 (7.4) | 33.1 (4.8) | 29.1 (6.1) |
| Ethnicity (%) | ||||
| White | 83% | 90% | 90% | 85% |
| African-American | 17% | 7% | 20% | 15% |
| Asian/Pacific Islander | 0% | 3% | 0% | 0% |
| Education (%) | ||||
| High school graduate | 43% | 50% | 30% | 60% |
| College graduate | 57% | 50% | 70% | 40% |
| Time since diagnosis (y) | 3.6 (2.2) | 3.3 (2.6) | 3.5 (2.3) | 3.5 (2.1) |
| Disease stage (%) | ||||
|
| 11% | 10% | 13% | 10% |
| Stage I | 54% | 27% | 67% | 45% |
| Stage II | 26% | 47% | 13% | 35% |
| Stage IIIA | 9% | 17% | 7% | 10% |
| Treatment (%) | ||||
| None | 6% | 13% | 13% | 0% |
| Radiation only | 43% | 23% | 47% | 40% |
| Any chemotherapy | 51% | 63% | 40% | 60% |
| Hormone therapy (%) | ||||
| None | 43% | 30% | 33% | 50% |
| Tamoxifen | 29% | 23% | 33% | 25% |
| Aromatase inhibitors | 29% | 47% | 33% | 25% |
| Physical activity questionnaire (min per week of moderate to vigorous intensity recreational activity) | 13.0 (24.0) | 12.0 (20.0) | 5.7 (10.2) | 19.4 (29.6) |
Note. No statistically significant differences between exercise, usual care groups, and exercise adherers versus nonadherers at baseline were observed.
Percent and number of participants defined as having the metabolic syndrome at baseline and six months.
| Number of metabolic syndrome criteria | Exercise baseline | Exercise 6 months | Usual care baseline | Usual care 6 months | Nonadherers baseline | Nonadherers 6 months | Adherers baseline | Adherers 6 months |
|---|---|---|---|---|---|---|---|---|
| 0 | 4 | 7 | 2 | 3 | 2 | 6 | 2 | 1 |
| 1 | 5 | 2 | 7 | 8 | 5 | 1 | 0 | 1 |
| 2 | 2 | 5 | 9 | 6 | 2 | 5 | 0 | 0 |
| 3 | 10 | 8 | 6 | 4 | 3 | 3 | 7 | 5 |
| 4 | 7 | 11 | 4 | 7 | 3 | 5 | 4 | 6 |
| 5 | 7 | 1 | 2 | 2 | 5 | 0 | 2 | 1 |
| Total | 24 | 20 | 12 | 13 | 11 | 8 | 13 | 12 |
| Percent | 69% | 57% | 40% | 43% | 55% | 40% | 87% | 80% |
Six-month change in metabolic syndrome variables in exercise intervention (n = 35) versus usual care (n = 30).
| Baseline (SD) | Mean change (SE) | Significance ( | |
|---|---|---|---|
| Waist circumference (cm) | |||
| Exercise | 91.7 (12.0) | −1.49 (0.76) | 0.508 |
| Usual care | 88.6 (15.6) | −0.75 (0.82) | |
| Systolic blood pressure (mm Hg) | |||
| Exercise | 123.1 (12.9) | 0.66 (2.25) | 0.080 |
| Usual care | 123.7 (18.7) | −5.23 (2.43) | |
| Diastolic blood pressure (mm Hg) | 0.304 | ||
| Exercise | 75.2 (6.8) | 0.75 (1.16) | |
| Usual care | 76.6 (9.1) | −1.02 (1.25) | |
| HDL-C (mg/dL) | |||
| Exercise | 52.7 (13.2) | 0.51 (1.65) | 0.325 |
| Usual care | 59.1 (15.4) | −1.90 (1.78) | |
| Triglycerides (mg/dL) | |||
| Exercise | 123.7 (53.7) | 1.40 (7.1) | 0.841 |
| Usual care | 117.8 (51.6) | −0.70 (7.7) | |
| Glucose (mg/dL) | |||
| Exercise | 104.9 (12.7) | −1.31 (1.21) | 0.029 |
| Usual care | 105.1 (10.7) | 0.6 (1.3) | |
| Metabolic syndrome | |||
| Exercise | −1.7 (3.3) | −0.09 (0.39) | 0.661 |
| Usual care | −2.2 (4.2) | −0.35 (0.42) |
Note. Negative z-score indicates below cut-off. Negative mean change score indicates improvement in criterion.
Six-month change in metabolic syndrome variables in exercise adherers (n = 20) versus nonadherers (n = 15).
| Baseline (SD) | Mean change (SE) | Significance ( | |
|---|---|---|---|
| Waist circumference (cm) | |||
| Adherers | 89.4 (12.5) | −2.48 (1.05) | 0.170 |
| Non-adherers | 94.8 (10.9) | −0.18 (1.22) | |
| Systolic blood pressure (mm Hg) | |||
| Adherers | 124.7 (14.4) | −1.99 (2.29) | 0.091 |
| Non-adherers | 121.0 (10.6) | 4.19 (2.65) | |
| Diastolic blood pressure (mm Hg) | |||
| Adherers | 76.2 (6.8) | −0.07 (1.00) | 0.226 |
| Non-adherers | 73.9 (6.9) | 1.84 (1.16) | |
| HDL-C (mg/dL) | |||
| Adherers | 54.8 (14.3) | 2.91 (1.42) | 0.016 |
| Non-adherers | 50.1 (11.5) | −2.67 (1.64) | |
| Triglycerides (mg/dL) | |||
| Adherers | 125.7 (63.2) | −3.13 (7.44) | 0.361 |
| Non-adherers | 121.0 (39.5) | 7.44 (8.60) | |
| Glucose (mg/dL) | |||
| Adherers | 102.6 (12.2) | −1.45 (1.58) | 0.898 |
| Non-adherers | 107.9 (13.2) | −1.13 (1.83) | |
| Metabolic syndrome | |||
| Adherers | −1.92 (3.7) | −0.76 (0.37) | 0.009 |
| Non-adherers | −1.36 (2.9) | 0.80 (0.42) |
WC: waist circumference, HDL-C: high-density lipoprotein cholesterol.